Combining Transarterial Therapy, Bevacizumab, and Immune Checkpoint Inhibitors for Liver Cancer Treatment
Author Information
Author(s): Yang Zhenyun, Wang Qianyu, Hu Li, Sima Xiaoxian, Wang Juncheng, Hu Dandan, Zhou Zhongguo, Chen Minshan, Zhang Yaojun, Fu Yizhen
Primary Institution: Sun Yat-sen University Cancer Center
Hypothesis
The study aimed to assess the efficacy and safety of combining transarterial therapy with bevacizumab and immune checkpoint inhibitors as a neoadjuvant treatment for locally advanced hepatocellular carcinoma.
Conclusion
The combination therapy of transarterial therapy, bevacizumab, and immune checkpoint inhibitors is a promising treatment strategy for patients with locally advanced hepatocellular carcinoma.
Supporting Evidence
- 54 patients received standard systemic therapy comprising bevacizumab combined with immune checkpoint inhibitors.
- 273 patients received neoadjuvant therapy of transarterial therapy combined with bevacizumab and immune checkpoint inhibitors.
- 79 patients (28.9%) underwent surgical resection after successful tumor downstaging.
- The median overall survival time was not reached in the neoadjuvant surgery group compared to 30.6 months in the surgery group.
- The median progression-free survival time was 19.2 months in the neoadjuvant surgery group compared to 6.3 months in the surgery group.
- The objective response rate across all patients receiving the combination therapy was 38.8%.
- The pathological complete response rate was 22.8% in the neoadjuvant surgery group.
Takeaway
Doctors combined three treatments to help patients with liver cancer, and it worked better than just surgery or other treatments alone.
Methodology
The study was a longitudinal, retrospective analysis of 440 patients with locally advanced hepatocellular carcinoma who received various treatment regimens.
Potential Biases
There is a risk of selection bias due to the retrospective nature of the study.
Limitations
The study was retrospective and conducted at a single center, which may introduce selection bias and limit generalizability.
Participant Demographics
Patients were aged 18-75 years, with a majority being male and having hepatitis infection.
Statistical Information
P-Value
P=0.0058
Confidence Interval
95% CI: 26.4-34.7
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website